NCT04503707View on ClinicalTrials.gov

Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Controlled Ovarian Stimulation
Interventions
DRUG

Follitropin Delta

The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.

Trial Locations (14)

Unknown

Hôpital Pellegrin, Bordeaux

Hôpital Femme Mère Enfant, Bron

Hopital Antoine Béclère, Clamart

Centre Hospitalier Intercommunal de Créteil, Créteil

Centre hospitalier de Lille-Hopital de Flandre, Lille

Institut de Médecine de la Reproduction (there may be other sites in this country), Marseille

CHU Montpellier, Montpellier

CHU Nantes Hôpital Hôtel Dieu, Nantes

Maternité Port Royal, Paris

Centre Hospitalier Intercommunal de Poissy, Poissy

Clinique Mutualiste La Sagesse, Rennes

Pierre OGER, Rueil-Malmaison

CMCO, Strasbourg

CHU Toulouse - Hôpital Paule de Viguier, Toulouse

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT04503707 - Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice | Biotech Hunter | Biotech Hunter